Sharon Mates, Chairman and CEO at Intra-Cellular Therapies, Inc. (ITCI), sold 134,228 shares at $73.32 ($9.8M) on 2024-08-30, disclosed to the SEC on 2024-08-30.
Scheduled sale ($9.8M) by Chairman and CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $72.44 | 29,832 | $2.2M | 22.2% |
| 2 | $72.44 | 29,832 | $2.2M | 22.2% |
| 3 | $73.25 | 5,772 | $423K | 4.3% |
| 4 | $72.73 | 28,203 | $2.1M | 21.0% |
| 5 | $72.73 | 28,203 | $2.1M | 21.0% |
| 6 | $73.32 | 6,193 |
| $454K |
| 4.7% |
| 7 | $73.32 | 6,193 | $454K | 4.7% |
| Total | $72.68 avg | 134,228 | $9.8M | 100% |
| Filing → |
| ITCI | SELL | 2024-08-23 | $18.0M | — | Filing → |
| ITCI | SELL | 2024-03-11 | $8.1M | — | Filing → |
| ITCI | SELL | 2024-02-27 | $3.1M | — | Filing → |